RNL Replay: SpA

Be sure to sign up for this week's TNR: Spondyloarthritis Spectrum on Tuesday April 23rd at 6:30pm EST. 

What is the difference between non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS)?

How does the clinical response to TNF inhibitors in nr-axSpA compare to AS?

Which imaging technique is preferred for detecting enthesitis due to its ability to assess both soft-tissue components and new bone formation?

What is the first-line treatment for patients with active AxSpA, according to the ASAS EULAR AxSpA Recommendations?

According to the 2023 ASAS-EULAR Recommendations, which treatment approach should be considered in patients with persistently high disease activity, despite conventional treatments?

According to the 2023 ASAS-EULAR Recommendations, IL-17i are contraindicated in patients with active Inflammatory Bowel Disease (IBD).

IL-23 inhibitors are highly effective in the treatment of AxSpA.

Which advanced therapy is superior in treating enthesitis in PsA/SpA?

I am a::

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.